Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells

Chimeric-antigen-receptor (CAR)-T-cell therapy is already widely used to treat patients who are relapsed or refractory to chemotherapy, antibodies, or stem-cell transplantation. Multiple myeloma still constitutes an incurable disease. CAR-T-cell therapy that targets BCMA (B-cell maturation antigen)...

Descripción completa

Detalles Bibliográficos
Autores principales: Reichman, Avinoam, Kunz, Alexander, Joedicke, Jara J., Höpken, Uta E., Keib, Anna, Neuber, Brigitte, Sedloev, David, Wang, Lei, Jiang, Genqiao, Hückelhoven-Krauss, Angela, Eberhardt, Franziska, Müller-Tidow, Carsten, Wermke, Martin, Rehm, Armin, Schmitt, Michael, Schmitt, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777942/
https://www.ncbi.nlm.nih.gov/pubmed/35055086
http://dx.doi.org/10.3390/ijms23020903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777942/
https://www.ncbi.nlm.nih.gov/pubmed/35055086
http://dx.doi.org/10.3390/ijms23020903

Ejemplares similares